Few scientific insights in recent years have rattled the gates of the medical community as vigorously as research on the gut microbiome\u2019s role in our overall health. We now know that, beyond its ability to churn our digestive process, this vast community of microbes influences our immune and respiratory systems as well as our cognitive and mental health. So, we shouldn\u2019t be surprised by the results of three new studies that suggest what happens in our guts also may affect how we age.<\/p>\n
In August, a team of Italian researchers published a paper<\/a> describing how a certain mix of microbes in the gut could affect the proteins in the blood that trigger inflammation, cardiovascular disease, and even macular degeneration. \u201cChanges in the gut microbiota influence various aspects of both gut and systemic immune and inflammatory responses, suggesting a link to the age-related decline in cardiovascular and immune function, often referred to as immune aging, immunosenescence, or inflammaging,\u201d lead study author Federica Grosso, MD<\/a>, writes<\/a> in the journal Aging-US<\/em>.<\/p>\n Grosso and her colleagues analyzed the data from 19 studies focusing on specific age-related illnesses and identified 91 specific instances in which a particular bacterial mix in the gut was associated with an increased risk of a particular disease. Macular degeneration, for instance, was linked to higher levels of coriobacteriaceae<\/em>, and heart disease was more likely to develop when enterobacteria<\/em> microbes caused lower levels of a certain protective protein.<\/p>\n Researchers also concluded that the effects of the gut\u2019s microbial mix may vary by blood type. People with blood type A, for example, may be more vulnerable to certain microbes that influence proteins associated with inflammation and cardiovascular health. Their findings suggest that clinicians may need to look beyond the gut microbiome and consider genetic factors, such as blood type, when managing age-related conditions.<\/p>\n Still, there\u2019s more work to be done, Grosso admits. \u201cWhile our analyses are robust and the results compelling, we were unable to elucidate the underlying biological mechanisms driving the observed causal relationships,\u201d she writes<\/a>. \u201cTherefore, any clinical application aimed at microbiome modulation remains premature.\u201d<\/p>\n What we can do, according to a Stanford University study<\/a> released last week, is monitor more closely the prescription drugs we\u2019re feeding to the microbes in our guts \u2014 because they may create an unhealthy microbiome.<\/p>\n Researchers tested 707 common medications on the microbe collections from nine fecal samples and found that 141 of the drugs disrupted the microbial mix in the gut. Some species were completely eviscerated, creating an environment that could trigger inflammation and other unhealthy consequences.<\/p>\n \u201cThe winners and losers among our gut bacteria can often be predicted by understanding how sensitive they are to the medications and how they compete for food,\u201d explains<\/a> lead study author Handuo Shi, PhD<\/a>. \u201cIn other words, drugs don\u2019t just kill bacteria; they also reshuffle the \u2018buffet\u2019 in our gut, and that reshuffling shapes which bacteria win.\u201d<\/p>\n Antibiotics are the primary culprit, of course, but Shi also cites a particular antidepressant as messing with the microbial mix. What\u2019s missing, however, is a comprehensive list of medications \u2014 or even classes of drugs \u2014 that may disrupt the gut\u2019s population. For that, we\u2019ll have to rely on a September study<\/a> from the University of Tartu in Estonia, which found that long-term use of a wide range of medications, including beta-blockers, protein-pump inhibitors, and steroids, contributed to a disrupted microbiome. The effects, the authors note, can linger for years after participants stopped using the drugs.<\/p>\n \u201cAlso, the drug burden is usually higher in older age groups,\u201d the authors write<\/a> in the journal mSystems<\/em>, \u201cso it can be expected that the microbiome in the older populations is even more affected.\u201d<\/p>\n My current pharmaceutical consumption doesn\u2019t include any of the above medications, but current research<\/a> offers little comfort. The calcium channel blocker I\u2019ve been taking, for example, may or may not be a problem. Some studies suggest it can remedy an imbalanced gut; others argue that it may disrupt it.<\/p>\n All this can create a bit of a conundrum for those of us who rely on pharmaceutical remedies to manage various chronic conditions. In some cases, these drugs can save lives. So, we\u2019re all caught in that murky territory between their salutary effects and their potential side effects. We can, as some experts advise, monitor those side effects and consult with our physicians to regulate the dosages, but it\u2019s hard to know at this point to what extent such manipulation would affect the mysterious microbial collection in our guts.<\/p>\n \u201cIf we can understand and model the ecosystem response,\u201d says Shi<\/a>, \u201cwe could one day choose drugs and accompanying diets or probiotics not only based on how well they treat a disease, but also on how they preserve or promote a healthy microbiome.\u201d<\/p>\n We\u2019re not there yet, so it\u2019s probably not worth worrying too much about it. Anxiety, after all, can lead to an upset stomach \u2014 and who knows what else.<\/p>\n The post PUMPING IRONY: Balancing Act<\/a> appeared first on Experience Life<\/a>.<\/p>","protected":false},"excerpt":{"rendered":" Few scientific insights in recent years have rattled the gates of the medical community as vigorously as research on the gut microbiome\u2019s role in our overall health. We now know that, beyond its ability to churn our digestive process, this vast community of microbes influences our immune and respiratory systems as well as our cognitive […]<\/p>\n","protected":false},"author":1,"featured_media":35430,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[],"class_list":["post-35429","post","type-post","status-publish","format-standard","has-post-thumbnail","category-life"],"publishpress_future_action":{"enabled":false,"date":"2026-10-25 15:33:49","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/posts\/35429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/comments?post=35429"}],"version-history":[{"count":0,"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/posts\/35429\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/media\/35430"}],"wp:attachment":[{"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/media?parent=35429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/categories?post=35429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gpnewswire.com\/news\/wp-json\/wp\/v2\/tags?post=35429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}